• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Schrodinger Inc.

    2/10/23 10:33:57 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SDGR alert in real time by email
    SC 13G 1 tm235555d5_sc13g.htm SC 13G

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

     

    SCHEDULE 13G

     

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No.  )*

     

    Schrödinger, Inc.

    (Name of Issuer)

     

    Common stock

    (Title of Class of Securities)

     

    80810D103

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x  Rule 13d-1(b)

    ¨  Rule 13d-1(c)

    ¨  Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 80810D103 13G Page 2 of 5 Pages 

     

    1. NAMES OF REPORTING PERSONS  
    ARK Investment Management LLC  
     
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP  
    (a)¨  
    (b)¨  
    3. SEC USE ONLY  
       
     
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
    Delaware, United States  
     

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5. SOLE VOTING POWER  
    3,852,037  
     
    6. SHARED VOTING POWER  
    0  
     
    7. SOLE DISPOSITIVE POWER  
    3,852,037  
     
    8. SHARED DISPOSITIVE POWER  
    0  
     

    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON  
    3,852,037  
     
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES  
    ¨  
     
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
    6.21%  
     
    12. TYPE OF REPORTING PERSON  
    IA  
     

     

     

     

    CUSIP No. 80810D103 13G Page 3 of 5 Pages 

     

    Item 1(a) Name of issuer:

     

    Schrödinger, Inc.

     

    Item 1(b) Address of issuer's principal executive offices:

     

    1540 Broadway, 24th Floor

    New York, New York 10036

     

    Item 2(a) Name of person filing:

     

    ARK Investment Management LLC

     

    Item 2(b) Address or principal business office or, if none, residence:

     

    ARK Investment Management LLC

    200 Central Avenue

    St. Petersburg, FL 33701

     

    Item 2(c) Citizenship:

     

    Delaware, United States

     

    Item 2(d) Title of class of securities:

     

    Common stock

     

    Item 2(e) CUSIP No.:

     

    80810D103

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

     

    (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

     

    (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

     

    (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);

     

    (e) x An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

     

    (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

     

    (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     

    (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

     

     

    CUSIP No. 80810D103 13G Page 4 of 5 Pages 

     

    (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     

    (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);

     

    (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    Item 4. Ownership

     

    (a)Amount beneficially owned:

     

    3,852,037

     

    (b)Percent of class:

     

    6.21%

    (c)Number of shares as to which such person has:

     

    (i)  Sole power to vote or to direct the vote:  3,852,037

     

    (ii) Shared power to vote or to direct the vote:  0

     

    (iii) Sole power to dispose or to direct the disposition of:  3,852,037

     

    (iv) Shared power to dispose or to direct the disposition of:  0

     

    Item 5. Ownership of 5 Percent or Less of a Class.

     

    Not applicable.

     

    Item 6. Ownership of More than 5 Percent on Behalf of Another Person.

     

    To the knowledge of the Reporting Person, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, a number of the shares which represents more than five percent of the number of outstanding class of the shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

     

    Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.

     

    Not applicable.

     

    Item 9. Notice of Dissolution of Group.

     

    Not applicable.

     

     

     

    CUSIP No. 80810D103 13G Page 5 of 5 Pages 

     

    Item 10. Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    The reporting persons agree that this statement is filed on behalf of each of them.

     

    Dated:    February 10, 2023

     

     

    ARK Investment Management LLC

         
      By: /s/ Kellen Carter
        Name:  Kellen Carter
        Title:    Chief Compliance Officer

     

     

    Get the next $SDGR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SDGR

    DatePrice TargetRatingAnalyst
    8/15/2025$20.00Buy → Neutral
    Citigroup
    8/14/2025$25.00Overweight
    Barclays
    7/3/2025$28.00Equal-Weight
    Morgan Stanley
    7/2/2024$29.00Outperform
    Leerink Partners
    12/5/2023$38.00Overweight
    KeyBanc Capital Markets
    5/5/2023$60.00Overweight
    Piper Sandler
    12/19/2022$23.00Neutral
    Goldman
    3/1/2022$55.00Buy
    Citigroup
    More analyst ratings

    $SDGR
    SEC Filings

    View All

    SEC Form 10-Q filed by Schrodinger Inc.

    10-Q - Schrodinger, Inc. (0001490978) (Filer)

    8/6/25 4:10:02 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    8/6/25 4:07:10 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrodinger Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Schrodinger, Inc. (0001490978) (Filer)

    6/18/25 4:09:48 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chodakewitz Jeffrey was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:37:45 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sender Gary was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:36:31 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Lynton Michael was granted 5,997 shares, increasing direct ownership by 53% to 17,247 units (SEC Form 4)

    4 - Schrodinger, Inc. (0001490978) (Issuer)

    6/20/25 4:35:05 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Schrodinger downgraded by Citigroup with a new price target

    Citigroup downgraded Schrodinger from Buy to Neutral and set a new price target of $20.00

    8/15/25 8:18:12 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Schrodinger with a new price target

    Barclays initiated coverage of Schrodinger with a rating of Overweight and set a new price target of $25.00

    8/14/25 8:23:26 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Morgan Stanley resumed coverage on Schrodinger with a new price target

    Morgan Stanley resumed coverage of Schrodinger with a rating of Equal-Weight and set a new price target of $28.00

    7/3/25 7:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Schrödinger Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

    Schrödinger, Inc. (NASDAQ:SDGR) today reported that on August 15, 2025, the company granted restricted stock units (RSUs) with respect to 1,875 shares of the company's common stock to two newly hired employees. These grants were made pursuant to the company's 2021 Inducement Equity Incentive Plan, were approved by the compensation committee of the board of directors pursuant to a delegation by the company's board of directors, and were made as a material inducement to such employees' acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation. The RSUs vest over four years, with 25 percent of such RSUs ve

    8/15/25 4:30:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Announces Discontinuation of SGR-2921 Program

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the discontinuation of the clinical development program for SGR-2921, its CDC7 inhibitor, which was being evaluated in a Phase 1 dose-escalation study in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes. Despite early evidence of monotherapy activity observed in the Phase 1 study, based on the profile observed to date, including two emergent events where SGR-2921 was considered to have contributed to two deaths in patients with AML, Schrödinger believes the path to development as a combination therapy would be difficult to pursue. The Phase 1 study was supported by preclinical data which had dem

    8/14/25 7:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c

    8/6/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Leadership Updates

    Live Leadership Updates

    View All

    Schrödinger Expands Executive Leadership Team with Appointment of Mannix Aklian as Chief Commercial Officer, Global Head of Software Sales and Marketing

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the expansion of its leadership team with the appointment of Mannix Aklian as executive vice president, chief commercial officer, global head of software sales and marketing. Mr. Aklian brings more than 25 years of experience in software sales and leadership roles within the biopharmaceutical and technology industries. Mr. Aklian will have global oversight of Schrödinger's account management teams and will be responsible for the continued growth of the company's software business, including the go-to-market strategy for enhancements and new products within Schrödinger's computational platform. "Mannix joins Schrödinger at a pivotal time as w

    5/29/25 8:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Expands Board of Directors with Appointment of Bridget van Kralingen

    Schrödinger, Inc. (NASDAQ:SDGR) today announced the appointment of Bridget van Kralingen to its Board of Directors, effective March 7, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250310010062/en/Bridget van Kralingen was appointed to Schrödinger's Board of Directors in March 2025. (Photo: Business Wire) "Bridget has a proven track record of growing global software businesses, and we are pleased to welcome her to our Board," said Ramy Farid, Ph.D., chief executive officer of Schrödinger. "Bridget's leadership experience overseeing strategic initiatives at global technology companies, including IBM, will be valuable to Sch

    3/10/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Appoints Geoffrey Porges as Chief Financial Officer

    Schrödinger, Inc. (NASDAQ:SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced the appointment of Geoffrey Porges, MBBS., as chief financial officer. Dr. Porges brings to Schrödinger more than 30 years of experience in executive, advisory and investment roles within the biopharmaceutical industry. As Schrödinger's CFO, he will lead all aspects of the company's financial operations and investor relations and corporate affairs activities. He will also oversee business development and strategic planning for the company's proprietary pharmaceuticals and biopharmaceutical collaborations. This press release features multim

    8/18/22 7:01:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Financials

    Live finance-specific insights

    View All

    Schrödinger Reports Second Quarter 2025 Financial Results

    Second Quarter Total Revenue of $54.8 Million, Software Revenue of $40.5 Million Maintains Full Year 2025 Revenue Growth Guidance and Lowers Operating Expense Guidance Company to Complete Phase 1 Data Package for SGR-1505 While Exploring Strategic Opportunities for Clinical Development Initial Clinical Data for SGR-3515 and SGR-2921 Expected in Fourth Quarter of 2025 Schrödinger, Inc. (NASDAQ:SDGR) today announced financial results for the quarter ended June 30, 2025. "In a highly dynamic macroenvironment, our ability to deliver solid second quarter results and maintain our 2025 revenue growth guidance is a testament to our strong customer relationships and the demand for proven c

    8/6/25 4:05:00 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger to Announce Second Quarter 2025 Financial Results on August 6

    Schrödinger (NASDAQ:SDGR) will report its second quarter 2025 financial results on Wednesday, August 6, 2025, after the financial markets close. The company will host a conference call and webcast at 4:30 p.m. ET. The live webcast can be accessed in the "Investors" section of Schrödinger's website and will be archived for approximately 90 days following the event. About Schrödinger Schrödinger is transforming molecular discovery with its computational platform, which enables the discovery of novel, highly optimized molecules for drug development and materials design. Schrödinger's software platform is built on more than 30 years of R&D investment and is licensed by biotechnology, phar

    7/25/25 8:30:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schrödinger Reports Encouraging Initial Phase 1 Clinical Data for SGR-1505 at EHA Annual Congress

    SGR-1505 was observed to have a favorable safety profile and was well tolerated, with encouraging preliminary efficacy in patients with relapsed/refractory B-cell malignancies Responses observed across a broad range of B-cell malignancies, including monotherapy responses in patients with CLL and Waldenström macroglobulinemia Management to host a webcast today at 8:00 a.m. ET Schrödinger, Inc. (NASDAQ:SDGR) today announced encouraging initial clinical data from its ongoing Phase 1, open-label, dose-escalation study of SGR-1505 in patients with relapsed/refractory B-cell malignancies. SGR-1505 was observed to be safe, well tolerated, and clinically active, with responses observed in mul

    6/12/25 7:00:00 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SDGR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Schrodinger Inc.

    SC 13G - Schrodinger, Inc. (0001490978) (Subject)

    11/13/24 4:30:25 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    2/13/24 5:13:59 PM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Schrodinger Inc. (Amendment)

    SC 13G/A - Schrodinger, Inc. (0001490978) (Subject)

    1/23/24 11:52:31 AM ET
    $SDGR
    Biotechnology: Pharmaceutical Preparations
    Health Care